January 26, 2016, the ceremony of “2015 China Financial Market Listed Companies Awards" was held at the Exchange Auditorium by China Financial Market, a renowned high-end financial magazine. Ten awards were granted at this ceremony, at which Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or the "Company"; stock code: 600196-SH, 02196-HK), China's leading pharmaceutical and healthcare company was awarded the "Best Investor Relations Award".

“2015 China Financial Market Listed Companies Awards" is set up by China Financial Market, a leading financial magazine which was founded with the need for high-end business executives in the capital market of Hong Kong. The award is dedicated to select model companies among Hong Kong-listed enterprises to recognize their performance of the past year in the business sector. Additionally, through issuing the awards, China Financial Market hopes to enable the public and investors to get a better understanding of award winners’ performance in the past year, to enable award-winning companies to impress the public more greatly with their corporate images and brand awareness, and to provide investment directions for investors as valuable reference. The ceremony is highly influential in Hong Kong, which attracted hundreds of executives of large listed companies both in Hong Kong and Mainland China, officials of financial sector of Hong Kong, and people in charge of the Hong Kong Association of Securities.

Since listing, Fosun Pharma executes strict corporate governance, strengthens the management of investor relations, which achieved remarkable results. After being selected in SSE 180, SHSZ300, SSE Dividend Index and SSE Corporate Governance Index, Fosun Pharma has also successfully been selected in SSE Private Enterprises 50 Index and SSE Social Responsibility Index. Strategic business of the Group covers many parts of value chain of pharmaceutical and healthcare industry. The business department covers pharmaceutics, medicine distribution and retail, healthcare services and diagnostic products and medical devices with maintaining a rapid growth and unlimited development potential. Fosun Pharma deserved the award of Best Investor Relations.

Fosun Pharma's management said that being awarded the "Best Investor Relations Award" is not only a recognition of the investor relations work of Fosun Pharma, but also a recognition of brand value of the Company. Fosun Pharma will continue to improve and innovate in the future management of investor relations, and further enhance the reputation and position of Fosun Pharma in the international capital market.